GEn1E Lifesciences Announces Partnership with BARDA to Advance its AI-powered Endotyping Program for ARDS Patients to Further Accelerate its Novel, Lead Compound GEn-1124
24 Oct 2023
Phase 2
PALO ALTO, Calif., Oct. 24, 2023 /PRNewswire/ -- GEn1E Lifesciences Inc. has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to support the development of the company's novel therapy for acute respiratory distress syndrome (ARDS), a devastating respiratory condition with no approved therapies and a 40% mortality rate.
The funding is provided via BARDA's Division of Research, Innovation, and Ventures (DRIVe) as part of the Host Directed Therapeutics Program to address a gap in the ability to stratify patients to predict patient outcomes to aid in clinical management.
The funding will be used to advance development of the company's ARDS endotyping program called ASPECT, which helps identify ARDS patients with distinct clinical outcomes. This approach will help further accelerate the development of GEn1E's novel, first-in-class, p38a:MK2 Signal Modifier therapy for ARDS, GEn-1124, which is currently enrolling patients in a company-sponsored Phase 2 study (NCT05795465).
The clinical heterogeneity of ARDS makes it difficult to understand disease progression and identify appropriate therapeutic options. Developing a pragmatic method for stratifying all ARDS patients, which can be used to identify patient trajectories and improve treatment in the clinical setting can benefit all providers and patients across the U.S.
"We thank BARDA for their support and look forward to advancing the development of GEn1E's first-in-class therapy for use in ARDS patients," stated Dr. Ritu Lal, CEO of GEn1E Lifesciences. "Heterogeneous populations and non-personalized treatment of ARDS patients is at the core of disease progression and poor clinical outcomes. Using AI and 'omics' data enables us to better define, diagnose and predict ARDS endophenotypes that can be used to target patients who will benefit from our therapy. Through this partnership with BARDA, we can change the trajectory of ARDS and help patients who do not have any options."
This project has been supported in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00063.
ABOUT GEN1E LIFESCIENCES:
GEn1E Lifesciences is a Clinical-Stage Phase 2 Techbio company accelerating novel and first-in-class immunomodulatory therapies for rare and inflammatory diseases. GEn1E Lifesciences is based in Palo Alto, California, with a laboratory in Mountain View, California.
GEn1E has created a well-differentiated "Platform-in-a-Mechanism" drug development model that uses artificial intelligence and machine learning (AI/ML) which spans the entire end-to-end drug development cycle. By using its integrated AI platform called RIDGE, the company has accelerated several significant milestones to build a portfolio of 21+ novel Signal Modifiers across two clinically valuable targets, which are actively being developed as first-in-class therapies for rare and inflammatory diseases with no treatments and hurtful health economics for patients and payors.
For more information on GEn1E, visit www.gen1e.com and follow GEn1E on LinkedIn.
SOURCE GEn1E Lifesciences Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.